128 related articles for article (PubMed ID: 29045545)
1. Liquid biopsy: another tool towards tailored therapy in colorectal cancer.
Tarazona N; Cervantes A
Ann Oncol; 2018 Jan; 29(1):7-8. PubMed ID: 29045545
[No Abstract] [Full Text] [Related]
2. The screening with the liquid biopsy for the rechallenge with anti-epidermal growth factor receptor antibodies in metastatic colorectal cancer A perspective based on pharmacological costs.
Giuliani J; Mantoan B; Candela MV; Napoli G; Muraro M; Mangiola D; Mandara M
Recenti Prog Med; 2023 Sep; 114(9):563-564. PubMed ID: 37530025
[No Abstract] [Full Text] [Related]
3. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
Chen SH; Tsai HL; Jiang JK; Sung YC; Huang CW; Yeh YM; Chen LT; Wang JY
BMC Cancer; 2019 Jun; 19(1):640. PubMed ID: 31253124
[TBL] [Abstract][Full Text] [Related]
4. Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation.
Sun Q; Liu Y; Liu B; Liu Y
Am J Med Sci; 2018 Mar; 355(3):220-227. PubMed ID: 29549923
[TBL] [Abstract][Full Text] [Related]
5. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
[TBL] [Abstract][Full Text] [Related]
7. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.
Normanno N; Cervantes A; Ciardiello F; De Luca A; Pinto C
Cancer Treat Rev; 2018 Nov; 70():1-8. PubMed ID: 30053724
[TBL] [Abstract][Full Text] [Related]
8. Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.
Gargalionis AN; Papavassiliou AG
Trends Cancer; 2017 Mar; 3(3):166-168. PubMed ID: 28718430
[TBL] [Abstract][Full Text] [Related]
9. Detection of telomerase activity in biopsy samples of colorectal cancer.
Fang DC; Young J; Luo YH; Lu R; Jass J
J Gastroenterol Hepatol; 1999 Apr; 14(4):328-32. PubMed ID: 10207781
[TBL] [Abstract][Full Text] [Related]
10. Role of liquid biopsies in colorectal cancer.
Wills B; Gorse E; Lee V
Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
[TBL] [Abstract][Full Text] [Related]
11. Cell-Free DNA in the Management of Colorectal Cancer.
Harlé A
Recent Results Cancer Res; 2020; 215():253-261. PubMed ID: 31605233
[TBL] [Abstract][Full Text] [Related]
12. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
Vymetalkova V; Cervena K; Bartu L; Vodicka P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.
Lu Y; Shi C; Qiu S; Fan Z
Oncotarget; 2016 Oct; 7(40):64766-64777. PubMed ID: 27074568
[TBL] [Abstract][Full Text] [Related]
14. Role of circulating tumor DNA in the management of patients with colorectal cancer.
Moati E; Taly V; Didelot A; Perkins G; Blons H; Taieb J; Laurent-Puig P; Zaanan A
Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):396-402. PubMed ID: 29627453
[TBL] [Abstract][Full Text] [Related]
15. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
García-Foncillas J; Alba E; Aranda E; Díaz-Rubio E; López-López R; Tabernero J; Vivancos A
Ann Oncol; 2017 Dec; 28(12):2943-2949. PubMed ID: 28945877
[TBL] [Abstract][Full Text] [Related]
16. Liquid Biopsy for the Management of Patients with Colorectal Cancer.
Yamada T; Matsuda A; Koizumi M; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Yokoyama Y; Hara K; Hotta M; Matsumoto S; Yoshida H
Digestion; 2019; 99(1):39-45. PubMed ID: 30554222
[TBL] [Abstract][Full Text] [Related]
17. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
[TBL] [Abstract][Full Text] [Related]
19. [Circulating tumor DNA and targeted therapy in colorectal cancer].
Huang YT; Xu JM
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):161-165. PubMed ID: 29575832
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Karapetis CS; Jonker D; Daneshmand M; Hanson JE; O'Callaghan CJ; Marginean C; Zalcberg JR; Simes J; Moore MJ; Tebbutt NC; Price TJ; Shapiro JD; Pavlakis N; Gibbs P; Van Hazel GA; Lee U; Haq R; Virk S; Tu D; Lorimer IA;
Clin Cancer Res; 2014 Feb; 20(3):744-53. PubMed ID: 24218517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
